723.65
-2.86%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.
Tatva Chintan Pharma Chem Ltd. has lost -20.17% in the last 6 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended